Výsledky vyhledávání - "Changyuan Kang"

Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trialResearch in context

Autor: Yangqing Zhan, Zhengshi Lin, Jingyi Liang, Ruilin Sun, Yueping Li, Bingliang Lin, Fangqi Ge, Ling Lin, Hongzhou Lu, Liang Su, Tianxin Xiang, Hongqiu Pan, Chaolin Huang, Ying Deng, Furong Wang, Ruhong Xu, Dexiong Chen, Ping Zhang, Jianlin Tong, Xifu Wang, Qingwei Meng, Zhigang Zheng, Shuqiang Ou, Xiaoyun Guo, Herui Yao, Tao Yu, Weiyang Li, Yu Zhang, Mei Jiang, Zhonghao Fang, Yudi Song, Ruifeng Chen, Jincan Luo, Changyuan Kang, Shiwei Liang, Haijun Li, Jingping Zheng, Nanshan Zhong, Zifeng Yang, Huang Yanming, M.M, Dong Haiping, M.D., Jinlin Hou, M.M, Shao Lei, M.D., Li Xiaoguang, M.D., Gao Yan, M.M.

Publikováno v: EClinicalMedicine, Vol 67, Iss , Pp 102359- (2024)

Summary: Background: Leritrelvir is a novel α-ketoamide based peptidomimetic inhibitor of SARS-CoV-2 main protease. A preclinical study has demonstrated leritrelvir poses similar antiviral activities towards different SARS-CoV-2 variants compared wi

Vyhledávací nástroje:

Upřesnit hledání